Major medical study reveals clopidogrel prevents heart attacks 14% better than aspirin with no extra bleeding risk.

April 10, 2009 (Boston, Massachusetts) — Smoking has become the latest factor shown to affect responsiveness to clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis), with a new post hoc analysis ...

A 600-mg clopidogrel loading dose reduced periprocedural ischemic cerebral events and rates of transient ischemic attack (TIA) and stroke at 30 days in patients undergoing carotid stenting in the ...

Antiplatelet therapy with the ADP P2Y12 receptor antagonist clopidogrel is recommended by current clinical practice guidelines to prevent atherothrombotic events in patients with coronary artery ...

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with ...

The antiplatelet drug clopidogrel helps prevent stent-associated thrombosis, but the antiplatelet effects are quite variable and the clinical consequences can be serious. New findings show that the ...

To the Editor: The conduct of the Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT) by Bhatt and colleagues (Nov. 11 issue) 1 is timely. Previous nonrandomized studies have ...

Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems Inc. and EMQN CIC have launched a new external quality assessment ...

ORLANDO -- The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds. The effect ...

Safety concerns of the concomitant use of clopidogrel with the proton pump inhibitors (PPIs) omeprazole or esomeprazole were published in May 2009 and February 2010 by European regulatory agencies.

San Francisco, CA—Despite the substantial incidence of atrial fibrillation (AF) in patients with valvular heart disease, there is a lack of data in the literature regarding optimal pharmacological ...